ULTIMOVACS
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
ULTIMOVACS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.ultimovacs.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
270 M NOK
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress LetsEncrypt SSL By Default IPv6
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Fagron SA
Fagron is a pharmaceutical company specializing in chemicals, equipment, and supplies solutions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Stroma Biosciences
Stroma Biosciences is a biopharma company that develops stroma therapies to tackle cancer.
Vaxxit
Vaxxit is a biopharmaceutical company developing vaccines against HIV.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.ultimovacs.com Semrush global rank: 7.86 M Semrush visits lastest month: 684
- Host name: 67.207.77.236
- IP address: 67.207.77.236
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Ultimovacs"
Ultimovacs - Crunchbase Company Profile & Funding
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response …See details»
Zelluna - Home
Finansavisen: Ultimovacs merges with Zelluna and raises 52 million NOK. At the same time, the CEO steps down immediately. 27, February, 2025See details»
Annual Report 2020 - Ultimovacs
On 11 January 2021, Ultimovacs announced that the Company will be participating in the randomized Phase II DOVACC collaboration trial with the Nordic Society of Gynaecological …See details»
Ultimovacs ASA - LinkedIn
Ultimovacs ASA | 3,923 followers on LinkedIn. Clinical-stage IO biotech on a mission to extend and improve the lives of cancer patients. | Ultimovacs is a biotech company developing novel ...See details»
Report 2021 - Ultimovacs
Ultimovacs has an extensive development program for UV1 with five phase II studies in five diferent indications including more than 650 patients: INITIUM (154 patients): Ultimovacs …See details»
Ultimovacs ASA (OSL: ULTI) Company Profile & Overview - Stock …
Oct 31, 2024 Company profile for Ultimovacs ASA (OSL: ULTI) with a description, list of executives, contact details and other key facts.See details»
Ultimovacs 2025 Company Profile: Valuation, Investors …
Information on acquisition, funding, investors, and executives for Ultimovacs. Use the PitchBook Platform to explore the full profile.See details»
Ultimovacs - Products, Competitors, Financials, Employees, …
About Ultimovacs Ultimovacs is a biotech company focused on developing immunotherapies within the pharmaceutical sector. The company specializes in creating peptide-based vaccines …See details»
Ultimovacs - Funding, Financials, Valuation & Investors
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.See details»
Ultimovacs ASA - Drug pipelines, Patents, Clinical trials - Synapse
Explore Ultimovacs ASA with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 117 news, and 1 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic …See details»
Ultimovacs - Contacts, Employees, Board Members, Advisors
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.See details»
Ultimovacs - Craft
Jan 28, 2021 Ultimovacs has 5 employees across 2 locations. See insights on Ultimovacs including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Ultimovacs - teaserclub.com
Ultimovacs is a pharmaceutical company focused on developing innovative immunotherapies for cancer treatment. Its lead product candidate, UV1, is a peptide-based vaccine designed to …See details»
Company Ultimovacs ASA OTC Markets - MarketScreener.com
Jan 24, 2024 Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical …See details»
FOURTH QUARTER 2020 REPORT Ultimovacs ASA
Organization and board hief Business Officer on 1 December 2020. At Ultimovacs, he will lead all business and corporate development efforts including building and maintaining strategic …See details»
Ultimovacs ASA: Annual Report 2022 – Company Announcement
Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of …See details»
Ultimovacs - Overview, News & Similar companies | ZoomInfo.com
Ultimovacs has announced that Ton Berkien,will be joining the organization as, Chief Business Officer, effective on, December 1st, 2020. In this role, Berkien will oversee business …See details»
Ultimovacs ASA: Approval and publication of prospectus
Oslo, 28 February, 2025: Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to …See details»
Ultimovacs bags EMA orphan drug status for cancer vaccine
Feb 20, 2024 The European Medicines Agency (EMA) has granted orphan drug designation to Ultimovacs for its universal cancer vaccine UV1 for the treatment of mesothelioma. The …See details»
生物制药业绩与裁员并驾齐驱，辉瑞裁员很令行业不安_CPHI制药 …
除此之外，诺华还预计将在未来两到三年在其全球开发部门（global development organization）中裁员1-2%。 在剥离山德士之后，诺华的组织分为五个单位，开发部门是其中之一，涵盖监管 …See details»